What stopping a GLP-1 medication means for your cardiovascular health

The study, published March 18, 2026, in BMJ Medicine (PMID 41877758), was led by Dr. Ziyad Al-Aly of Washington University School of Medicine in St. Louis and the VA Saint Louis Health Care System.

Researchers compared two groups of U.S. veterans with type 2 diabetes followed for up to three years: 132,551 people prescribed GLP-1 receptor agonists and 201,136 people prescribed sulfonylureas (another class of type 2 diabetes medication). They evaluated treatment status every six months and tracked major adverse cardiovascular events — heart attack, stroke, and death.

Key findings:

• Continuous use over three years was linked to an 18% reduction in major cardiovascular events compared with the sulfonylurea group — or roughly 4 fewer events per 100 people.
• Stopping for six months was linked to a 4–8% increase in cardiovascular risk compared with continuous GLP-1 use.
• Stopping for two years was linked to up to a 22% increase in cardiovascular risk.
• Those who stopped and restarted experienced an average 12% risk reduction — less than the 18% reduction seen in those who stayed on the medication continuously. Longer gaps corresponded to smaller recoveries.
• Over the course of the study, 26% of GLP-1 users stopped treatment entirely; about 23% had a gap of six months or more before resuming.

Dr. Al-Aly described it this way: “The cardiovascular protection provided by GLP-1 medication builds slowly, but it erodes quickly. As little as one year off the drug was more than enough for study participants to lose benefits cultivated over years of continuous treatment.”

Participants who took GLP-1s for two or two-and-a-half years before stopping for the remainder of the study still gained significant risk reduction (7% and 15%, respectively) at the end of the trial. Those who stopped before 18 months saw no significant risk reduction compared with the sulfonylurea group at the endpoint.

In other words, the benefit is cumulative — and time-dependent in both directions.

Restarting after a gap helped, but not completely. Patients who resumed treatment gained an average 12% risk reduction — compared with 18% for those who never stopped. Longer interruptions corresponded to smaller recoveries.

Al-Aly characterized this as discontinuation leaving “a lasting scar.” The protective effect does not reset cleanly when treatment resumes — at least not within the three-year window of this study.

The study introduces a new dimension to the stopping conversation. Until now, the well-documented consequence of stopping GLP-1 therapy was weight regain — typically significant and rapid for most people. This study suggests there may be cardiovascular consequences that occur independently of, or in addition to, weight regain.

Al-Aly's team observed that stopping GLP-1 treatment was associated with a return of inflammation, blood pressure elevation, and cholesterol changes — what he calls “metabolic whiplash.” Weight regain is visible. This metabolic reversal is not.

If you are considering stopping your GLP-1 for any reason — cost, side effects, reaching your goal, or a supply issue — this data suggests that conversation with your prescriber should explicitly include cardiovascular implications, not just the weight piece.

This study has real constraints that belong in any honest reporting:

• Population: U.S. veterans with type 2 diabetes. This group has elevated baseline cardiovascular risk compared with the general population. The findings may not apply equally to people taking GLP-1s for obesity without T2D, or to younger, healthier populations.
• Comparator: The control group took sulfonylureas, not a placebo. GLP-1s and sulfonylureas have different cardiovascular risk profiles. The comparison isolates relative effect, not absolute.
• Observational design: This was a real-world cohort study, not a randomized trial. There may be unmeasured differences between people who stayed on GLP-1s and those who stopped — including differences in overall health, access to care, or reasons for stopping.
• Duration: Three years. It is not known whether the patterns would change with longer follow-up.

Many people stop GLP-1 medications because of cost or insurance coverage gaps — not by choice. This study makes that a cardiovascular issue, not just a metabolic one.

If cost or access is the reason you're considering stopping, talking with your prescriber about bridges, alternatives, or prior authorization appeals takes on additional urgency when cardiovascular risk is part of the picture.

• Given my cardiovascular risk profile and the reason I'm considering stopping, what does this evidence mean for my specific situation?
• If I need to stop temporarily because of cost or access, what should I watch for, and how quickly should I plan to restart?
• Is there a tapering approach, or a lower dose that could preserve some benefit if a full dose is not sustainable?
• If I've already had a gap in treatment, does restarting now still make cardiovascular sense?

• Blood pressure, at home if possible, especially in the weeks after stopping or restarting
• Any return of symptoms that were being managed through GLP-1 therapy (including appetite, blood sugar in people with T2D)
• Weight trends after any change in treatment status
• Any cardiovascular warning signs — chest discomfort, shortness of breath, unusual fatigue — and report them to your clinician promptly

The WashU BMJ Medicine study is the largest real-world analysis to date of GLP-1 discontinuation and cardiovascular outcomes. Its findings are meaningful. They are also population-specific, observational, and three years in duration.

What they establish clearly: for adults with type 2 diabetes, stopping GLP-1 treatment is not a neutral act for cardiovascular health. The risk increase is measurable, relatively rapid, and only partially reversible by restarting.

What they cannot tell us: whether the same pattern holds for obesity patients without T2D, whether newer GLP-1 formulations would show the same pattern, or how these findings should be weighted against non-cardiovascular reasons a person might stop treatment.

Before stopping your GLP-1 medication for any reason — bring this study to your prescriber. That conversation, with your specific history on the table, is the right place to make this decision.

Medical disclaimer: This content is for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.

Sources

• Al-Aly Z et al. Glucagon-like peptide 1 receptor agonist discontinuation and risks of cardiovascular events. BMJ Medicine March 18, 2026. PMID 41877758. pubmed.ncbi.nlm.nih.gov
• Washington University School of Medicine in St. Louis. Stopping GLP-1 drugs can quickly erase cardiovascular benefits. March 18 2026. medicine.washu.edu